Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Compare 6-month and 12-month emergency funds to determine the best target for your finances, weighing liquidity, security, and timelines.
24,819 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
iQIYI’s stock trades near $1 after a disappointing Q1 report, but the company’s AI pivot and new capital moves set up...
From a kitchen studio to a coveted CEO audience, this profile traces how David Senra built podcast influence by leani...
SpaceX has joined the NASDAQ 100, but veteran skepticism remains. Famed investor jeremy gratham says today’s hype cou...
Synopsys stock faces near-term headwinds despite rising revenue, as margins and debt weigh on the long-term outlook. ...
A one-time lottery windfall can trigger IRMAA surcharges, lifting Medicare premiums for the following year. Here's ho...
A snack brand’s take-private deal sent its stock surging and offered a clear lesson for investors. This guide breaks ...
A wave of catalysts and improving charts push XRP, Bitcoin and Ethereum higher, with traders eyeing potential fresh h...
NVIDIA posted a record quarter, sending its stock to new highs while signaling sustained AI demand. The week brought ...
XRP is mired in a short-term pullback as buyers hesitate near $1.40. With two red weekly candles, analysts flag a pot...
In a surprising policy shift, trump announces sanctions relief aimed at easing global oil prices. Traders are watchin...
United Airlines faces near term pressure from higher fuel costs, yet the Street remains optimistic with a consensus t...